Arcutis Biotherapeutics stock had its Relative Strength (RS) Rating upgraded from 67 to 76 Thursday — a welcome improvement, but still short of the 80 or higher score you look for.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves. See if Arcutis Biotherapeutics stock can continue to rebound and clear that threshold.
Is Arcutis Biotherapeutics Stock A Buy?
Arcutis Biotherapeutics stock is working on a consolidation with a 17.75 entry. See if the biotech stock can clear the breakout price in heavy volume.
The Calif-based biotech company showed 0% earnings growth in the latest quarterly report. Revenue gains came in at 33%.
Arcutis Biotherapeutics stock earns the No. 99 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
